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Substance use disorders are complex
diseases with signiﬁcant heritability
and psychosocial susceptibility factors
that develop with neurobiological and
neurocognitive adaptations after
chronic exposure to drugs of abuse.
Individual effects of genes and psycho-
social factors are modest in most
cases. Recent large sample collections
have began to identify single factors
with conﬁdence.
New molecular, imaging and environ-
mental collection technologies have
vastly increased the depth of data
per individual. New computation and
data management technologies no
longer limit complex statistical model-
ing routines.
Machine learning algorithms are begin-
ning to be applied to SUD data. New or
streamlined artiﬁcial intelligence algo-
rithms are disrupting all industries.
These have direct applications to bio-
marker/biosignature development.
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baurley@biorealm.ai (J.W. Baurley).There are limited biomarkers for substance use disorders (SUDs). Traditional
statistical approaches are identifying simple biomarkers in large samples, but
clinical use cases are still being established. High-throughput clinical, imag-
ing, and ‘omic’ technologies are generating data from SUD studies and may
lead to more sophisticated and clinically useful models. However, analytic
strategies suited for high-dimensional data are not regularly used. We review
strategies for identifying biomarkers and biosignatures from high-dimensional
data types. Focusing on penalized regression and Bayesian approaches, we
address how to leverage evidence from existing studies and knowledge
bases, using nicotine metabolism as an example. We posit that big data
and machine learning approaches will considerably advance SUD biomarker
discovery. However, translation to clinical practice, will require integrated
scientiﬁc efforts.
Biosignatures in Substance Use Disorders
Biomarkers for substance use disorders (SUDs) are available for drug use based on detection
of the substance or its metabolites, for example, ethyl glucuronide for alcohol [1], tetrahy-
drocannabinol for marijuana [2], and cotinine for tobacco [3]. They are not, however, readily
available for the neurobiological modiﬁcations that result in the maladaptive behaviors we
describe as addiction [4]. Clinical phenotyping has been used to assess the presence and
severity of SUDs and comorbid psychiatric disease and to evaluate treatment options. We
now have massive data on patients with SUDs [e.g., genomics and other omics (see
Glossary), and imaging on the structure and function of the brain]. How can we use this
data in biomarker/biosignature discovery? The ability to combine omics with each other and
with complex neurocognitive or imaging data promises to deliver biosignatures that will reﬂect
the behavioral and biological modiﬁcations that occur in addiction. Standard biostatistical
analysis that has been so useful in clinical research does not perform well in this high-
dimensional environment where variables vastly outnumber patients [5]. Studies of SUDs and
treatments are beginning to use more comprehensive modeling approaches. In one example,
data from diverse domains (brain, personality, cognition, demographics, and genetics) were
incorporated into a highly predictive model of current and future alcohol abuse in adolescents
[6]. In another recent example, researchers performed an integrative analysis to link genomic
variation with expression changes in the brains of alcohol-dependent individuals [7]. While
these studies point to an encouraging trend, there still appears to be a gap between the
massive data available and the routine use of computational and statistical tools in biomarker/
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Glossary
Bayes factors: a statistical measure
that quantiﬁes the evidence for a
hypothesis relative to an alternative
hypothesis.
Bayesian: a method of statistical
inference in which Bayes’ theorem is
used to update the probability for a
hypothesis as more evidence or
information becomes available.
Bupropion: an FDA approved non-
nicotine smoking cessation
pharmacotherapy, most commonly
prescribed in an extended-release
formulation.
Edge: an element that connects two
nodes in a graph, sometimes
deﬁning relationships or assigning
weights.
Genome-wide association scan:
an epidemiological study designed to
evaluate the statistical association
among genotypes and traits or
diseases of interest.
High-dimensional data: data
characterized by a large number of
dimensions. The reﬁnement of ‘large’
within this context is still a topic that
is debatable. Many deﬁne ‘large’
relative to the size of the available
data; that is, the data is high
dimensional when the number of
dimensions (P) exceeds the number
of observations (N).
Learned weights: the estimated
model parameters, such as
regression coefﬁcients.
Measures of ﬁt: statistical
techniques designed to assess how
well a model ﬁts a data set.
Model complexity: typically refers
to the size of the model; that is, the
number of free parameters.
Nicotine replacement therapy:
smoking cessation therapy providing
the patient with nicotine; there are
ﬁve FDA-approved modes of
administration of NRTs: gum, patch,
lozenge, spray, and inhaler.
Node: a point at which lines or
pathways intersect or branch.
Omics: the exhaustive and
systematic study of a molecular
analyte (DNA, RNA, protein, or
metabolites, and modiﬁcations to the
same) from one or multiple (‘meta’)
species, sometimes in relation to a
disease or trait, for example,
substance-use behavior.
Operators: a mapping that takes as
inputs elements of a space andBiosignature discovery provides a way of combining many variables (e.g., genetic effects,
voxels in neuroimaging) into meaningful models. Without models of net effects, it is difﬁcult to
interpret many small effects, especially given complex correlations in data. High-dimensional
data is also becoming quite common on large populations, while measures of molecular
phenotypes, which may not be cost effective or safely accessed, are less commonly collected.
Biobanks of large cohorts with genomic data are becoming available, such as the Million
Veteran Program, the All of Us Research Program, UK Biobank, GenomeAsia 100K, and even
direct-to-consumer services such as 23andMe and Helix. While there is recognition that
additional omics are necessary to understand the inﬂuence of genotype on phenotype, the
most commonly available data will remain genotypic. Using a biosignature approach, there are
opportunities to gain new biological insights and assess multiple predicted phenotypes. This is
one of the premises behind transcriptome-wide association studies [8]. Using studies where
both genomic and transcriptomic data are available, the tissue-speciﬁc relationship between
DNA (genotypes) and RNA (gene expression) can be modeled to generate predictive models
[9]. These models are then used in genomic data to predict expression and association to
diseases or quantitative traits [10,11].
Using high-dimensional data to proﬁle and predict SUD molecular phenotypes and outcomes
is a new development path (see Figure 1, Key Figure). Discovery is driven by statistical
learning algorithms suited for detection of biosignatures from high-dimensional data. The
learned biosignatures are then validated and applied in various use cases (e.g., to identify
subgroups at risk of SUDs or as tools to optimally select treatments). We advocate propa-
gating the data from new observations and predictions back into the development cycle to
allow for continuous improvement of the models (Figure 1). We see great promise in statistical
learning to discover and validate biosignatures, but recognize that the translational path into
clinical settings will have some unique challenges. In the next sections, we illustrate the
workﬂow presented for this model (Figure 1) by learning biosignatures of nicotine metabolism
in high-dimensional genomic data.
Application to Nicotine Metabolism
We use the nicotine metabolism pathway as a motivating example for the utility of statistical
learning to discover and use SUD biosignatures from high-dimensional data. Nicotine
metabolism is strongly inﬂuenced by genes; the majority of variance (74%) is due to additive
genetic inﬂuence [12,13]. The cytochrome P450 monooxygenase 2A6 (CYP2A6) is the
dominant but not exclusive metabolic enzyme in nicotine metabolism [14]. Early work
established that the ratio of the ﬁrst two major metabolites of nicotine [trans-30-hydroxyco-
tinine:cotinine, known as the nicotine metabolite ratio (NMR)] can serve as a biomarker of
nicotine metabolism [15]. The NMR is estimated biochemically [16] or via prediction using
CYP2A6 genotypes [17,18]. Genes coding for numerous additional oxidases (FMO3, AO,
CYP2B6, POR, and AKR1D1) and the uridine diphosphate glycosyltransferases (UGTs) have
been found to be associated with nicotine metabolism through individual genetic variants, or,
less commonly, gene/protein expression, or protein activity analyses [19–27]. Moreover, in
diverse populations and using blood, saliva, and urine biospecimens from smokers, or using
labeled nicotine and cotinine in clinical laboratory studies using blood and urine, nicotine
metabolism has been reported to vary by ancestry [28–31], age, gender, body mass index,
estrogenic hormones, and alcohol and cigarette consumption [32].
In addition to pharmacologic investigations of nicotine metabolism [14], investigators have
studied the inﬂuence of nicotine metabolism on smoking cessation retrospectively, using either
the biochemical measure of the NMR [33–35] or genotypes associated with reduced NMR222 Trends in Molecular Medicine, February 2018, Vol. 24, No. 2
returns other elements of the same
space.
Penalized regression: a regression
method that makes use of a penalty
structure to regularize regression
coefﬁcients, also known as
regularized and shrinkage regression.
Posterior predictive distribution:
the distribution of possible
unobserved values conditional on the
observed values.
Posterior probability: the
conditional probability of an event
after observed/known evidence is
taken into account.
Prediction bias: the bias associated
with a prediction, with bias referring
to the tendency of a measurement
process to over- or under-estimate
the value of a population parameter.
Prediction variance: the variability
associated with a prediction, with
variance being a measure of
dispersion/deviation from a mean.
Priors: probability models which are
meant to reﬂect a modeler's a priori
knowledge of the parameters in the
data model before some evidence is
taken into account.
Single nucleotide polymorphism:
a variation in a single nucleotide that
occurs at a speciﬁc position in the
genome.
Statistical learning algorithms:
algorithms which implement different
statistical learning techniques. That
is, algorithms which complete
function estimation from a given
collection of data.
Varenicline: a smoking cessation
aid that is a partial agonist of a4b2
nicotinic acetylcholine receptors.
Versioning: the variables selected in
a model and its estimated weights
may change as more data becomes
available. Careful tracking of each
iteration of the data, algorithms,
models, predictions, and validations
allows biomarkers and biosignatures
to continually improve.
Voxels: much like a pixel in a two-
dimensional image, a voxel is a tiny
cube that contains information and is
used to build a three-dimensional
image.
Key Figure
Biosignature Development Workflow
Figure 1. Data where the number of variables vastly outnumbers the number of samples (high dimensional data) are
becoming commonplace in studies of substance abuse disorders and treatment approaches. We present two approaches
(penalized regression and Bayesian learning) for detecting the combination of variables (biosignatures) predictive of SUD
phenotypes (e.g., nicotine metabolism). Biosignature detection is followed by validation, then prospective assessment of utility
for translation to clinical practice.
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[33,36,37]. There has been one prospective analysis of the inﬂuence of the NMR on smoking
cessation, examining the efﬁcacy of nicotine replacement therapy (NRT), varenicline and
placebo in slow and normal nicotine metabolizers, with the NMR determined from direct
biochemical measurement [38]. Note that biomarkers of nicotine metabolism, as studied in
the literature, have differed somewhat depending on the genotyping approach, biochemical
ratios, and cutoffs selected, as well as on the clinical or population samples used to establish
the biomarker; one common dichotomization stratiﬁes individuals with normal metabolism
versus slow metabolism.
In general, retrospective studies of smokers, randomized to NRT or placebo, have shown that
individuals with biomarkers of slow metabolism, whether deﬁned by genotype or biochemical
ratio, were signiﬁcantly more likely to remain abstinent than individuals with normal metabolism.
In one retrospective analysis [37], individuals with slow nicotine metabolism did not beneﬁt (no
reduction in relapse proportions) from active treatment (NRT, bupropion, or combined active
treatment) compared to placebo treatment, while individuals with fast nicotine metabolism did
beneﬁt from active treatment. In the prospective trial stratiﬁed by the NMR, individuals with
normal nicotine metabolism responded signiﬁcantly better to active treatment than placebo,
and those randomized to varenicline responded signiﬁcantly better than those randomized to
NRT [38]. Together, these ﬁndings suggest that treatment success can be optimized by
assigning treatment to patients by their NMR status, for example, assigning more active
pharmacotherapy to normal metabolizers and less active pharmacotherapy to slow metab-
olizers. A clinical trial using the NMR to assess nicotine metabolism and provide metabolism-
matched pharmacotherapy is in progress [39]. Biosignatures for predicting nicotine metabolism
in clinical trials of smoking cessation therapies, and in cohorts being studied for tobacco-related
behaviors, diseases, and exposures, will be useful to characterize the role of nicotine metabo-
lism in these complex outcomes [40].
The prior knowledge, results, and data described above can be directly used in biosignature
development (inputs in Figure 1). Statistical learning algorithms (described in the next sections)
can be applied to detected biosignatures of nicotine metabolism. These biosignatures (once
validated) can be used to predict other outcomes (such as smoking cessation) or to personalize
treatments (e.g., bupropion, varenicline, or NRT for a smoker; Figure 1).
Biosignature Detection in High-Dimensional Data
The data layout for biosignature learning is shown in Figure 2. One or more SUD studies have
both high-dimensional data (e.g., genomic) and molecular phenotypic data (e.g., metabolites).
For simplicity, it was assumed that the clinical factors were binary and that the genotypes were
single nucleotide polymorphisms (SNPs), coded by the number of copies of the minor allele
[41]. Millions of genotyped and imputed SNPs can be available. The relevant variables (the
biosignature) and its net effects on a predictable molecular phenotype (denoted Z in Figure 2)
are then learned using statistical algorithms. Once the relationships are represented in models,
they can be applied to new data for prediction and assessment of the outcomes of interest
(denoted Y in Figure 2). For nicotine metabolism, these could be smoking cessation, lung
cancer risk, treatment response, and so on. Of note, the molecular phenotype does not need to
be measured once the model is learned, as it can be predicted from the biosignature,
sometimes from summary statistics [10,11].
Simple models consider only one genetic variant at a time. A genome-wide association scan
(GWAS) represents millions of tests for genetic associations with the trait or outcome [5]. There
have been four GWASs using the NMR as the trait to date [13,42–44]. These four GWASs used224 Trends in Molecular Medicine, February 2018, Vol. 24, No. 2
Figure 2. Biosignatures of Nicotine Metabolism. Nicotine metabolism biosignatures are learned from genotypes G
and clinical C data in laboratory studies of nicotine metabolism. Nicotine metabolism is then predicted (Zpred) in existing or
new observations using the biosignatures and corresponding model weights. The predicted nicotine metabolite ratio can
them be associated with clinical outcomes Y, such as smoking cessation (1 indicates success). Adapted from Gusev et al.
[10].readily available GWAS genotyping arrays, as well as typical statistical pipelines for genotype
cleaning and imputation via the 1000 Genomes Project resourcei. Two GWASs represented
meta-analyses of single ancestries [13,44] – one was a multiancestry meta-analysis [42] and the
other was a multiancestry mega-analysis [43]. As expected, in all four scans, variants in and
near CYP2A6 on human chromosome 19 (the gene encoding the primary nicotine metabolic
enzyme) were associated with the NMR at genome-wide signiﬁcance. In each GWAS, the most
signiﬁcant associations were located proximal, within, and distal to CYP2A6, with individual
SNPs, signiﬁcance ranks, and span of association being dependent upon study, sample size,
and ancestry composition. We and others [13,42,43] have noted complex patterns of associ-
ation with the NMR that span into nearby genes, including CYP2B6 (Figure 3) [42]. Given that
there are complex patterns of marginal associations and that the number of variables exceed
the sample size (known in statistics as P > N), how does one deﬁne a biosignature of nicotine
metabolism based on genomic data?
The dimensionality problem can be addressed in part by using existing knowledge and results
to reduce the model space (Figure 1). From available genome-wide data [42], we selected 11
genomic regions implicated in nicotine metabolism for modeling. We identiﬁed the relevant
regions using a combination of knowledge bases (such as PharmGKB [45]) and recent literature
[19–27]. We then used algorithms to reduce model complexity. The rationale here was that
there can be too many variables for a human to decide which should go in a model.
Two classes of statistical learning algorithms can be used for selecting which variables should
be in a model (Box 1) and estimating their joint effects on an outcome [46]. These algorithms
explore a trade-off between model complexity, prediction bias, and prediction variance.
That is, prediction bias can be reduced by increasing model complexity. Alternatively, one can
also trade prediction bias for reduced variance using approaches to reduce complexity. TheTrends in Molecular Medicine, February 2018, Vol. 24, No. 2 225
Figure 3. Genetic Associations with Nicotine Metabolism in the CYP2A6 Region of Human Chromosome 19. The variants selected using penalizedgoal is to ﬁnd a sweet spot, selecting the right model complexity to minimize prediction error
[47,48].
The First Approach: Penalized Regression
Penalized regression approaches add a penalty term to the typical optimization problem
[47,48]. That is, many penalized regression methods estimate the regression coefﬁcients by
minimizing a penalized residual sum of squares which is given by:
b^ ¼ argminb
XN
i¼1
yi  b0 
XP1
j¼1
b1jCij 
XP2
j¼1
b2jGij 
XP3
j¼1
b3jZij
  !2
þ Pðb; lÞ;
where l represents a collection of tuning parameters which implicitly controls the model
complexity, b denotes the collection of all the regression coefﬁcients, and P(, ) is a penalty
function [47,48]. For example, a penalty function of the form
Pðb; lÞ ¼ l1a
X3
k¼1
XPk
j¼1
jbkjj þ l2ð1  aÞ
X3
k¼1
XPk
j¼1
b2kj;
could be considered, where setting a = 1 results in the least absolute shrinkage and selection
operator (LASSO) [49], a = 0 provides the usual ridge estimator [50], and a 2 (0, 1) results in the
elastic net [51]. In general, through regularization, the ridge estimator is able to provide better
prediction performance by exploiting the so-called bias versus variance trade-off and can be
used (unlike standard ordinary least squares) to uniquely estimate the regression coefﬁcients
when P > N [50]. Unlike ridge, LASSO provides a parsimonious model through automatic
variable selection, though it has been empirically shown that, in comparison to LASSO, ridge
maintains a higher level of prediction accuracy in the face of correlated predictors [49]. The
elastic net is a blend of ridge and LASSO, which attempts to gain from their strengths and
overcome their individual weaknesses. In particular, the elastic net makes use of a linear
combination of the ridge and LASSO penalties and can therefore complete automatic variable226 Trends in Molecular Medicine, February 2018, Vol. 24, No. 2
Box 1. Model Speciﬁcation
Generalized linear models can be used as a foundation for biosignature discovery and predicting nicotine metabolism
from genomic and clinical data [88]. The conditional mean of Yi, the observed molecular phenotype or outcome of
individual i, is related to P explanatory variables through the link function g():
gðmiÞ ¼ b0 þ
XP1
j¼1
b1jCij þ
XP2
j¼1
b2jGij þ
XP3
j¼1
b3jZij ;
where there are P1 clinical factors (e.g., age, sex, BMI), P2 genetic markers, and P3 derived variables, denoted by Cij, Gij,
and Zij, respectively, with P = P1 + P2 + P3. bkj represents the usual regression coefﬁcients. The derived variables can be
interaction terms of other functions that combine sets of other variables. In the analysis described herein, the natural
logarithm of NMR is used as the response variable so that g() can be taken to be the identity link.selection while maintaining a high degree of prediction accuracy in the face of correlated
predictors [51].
There are numerous algorithmic varieties of this general approach, with different properties in
terms of handling correlation, sparsity, and picking out features in the data [48]. Moreover,
extensive work has shown that none of the penalized regression procedures are universally
better in all situations [48,52]. So it is natural to posit the question, ‘What penalized regression
method should I use?’ Our retort, ‘Why choose one?’
Different penalized regression procedures can be applied to the motivating nicotine metabolism
data; for details on these algorithms, their implementation, and their penalty structures see
Table 1. In particular, Table 1 provides nine different penalized regression methods, citations
that present the relevant background on each procedure, and R-packages that can be utilized
to implement each of the methods. As discussed above, these algorithms have different
properties and therefore provide diverse insights into the data. We believe that the collection
of models (the ensemble) characterizes the biosignature of this molecular phenotype. This is
demonstrated in Figure 4, where the rows represent the biosignatures learned by the different
algorithms applied to the nicotine metabolism data [53]. The unshaded portions represent the
genetic signature identiﬁed by each approach. As expected, a handful of SNPs (out of 3752)
were selected in all the models [53]. The largest model included 63 SNPs, but more parsimo-
nious models explained NMR just as well with fewer SNPs (58–62% NMR) [53]. The genetic
biosignature found by these methods in human chromosome 19 are overlaid on the marginalTable 1. Penalized Regression Algorithms Applied to the Nicotine Metabolism Dataseta
Method R-package Refs
LASSO glmnet [49]
Elastic net glmnet [51]
Adaptive LASSO parcor [89]
SCAD ncvreg [90]
MCP ncvreg [91]
SCAD-Ridge ncvreg [92]
MCP-Ridge ncvreg [92]
Dantzig selector ﬂare [93]
lq LASSO ﬂare [94]
aThe table includes the R packages implementing it, and the primary research articles describing the algorithms.
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Figure 4. An Ensemble of Models to Deﬁne Biosignatures. The rows highlight (unshaded) the sets of SNPs selected by different penalized regression algorithmsresults in Figure 3. This highlights additional signals near the CYP2A6 and CYP2B6 genes that
may have been missed in a more traditional approach. The collection of variables that is
predictive of an individual's nicotine metabolism is more than those discoverable using
standard genetic association scans. To predict nicotine metabolism with new genotypes,
one simply applies the learned weights to the SNP biosignatures [53]. The predicted nicotine
metabolism can be then applied in additional association or clinical studies.
The differences in the SNPs selected by the penalized regression algorithms (Figure 4) suggest
that there are multiple ‘good’ models and one may want to average over the strengths of a set of
models when making predictions [54,55]. This leads to the second approach where model
uncertainty can be quantiﬁed [54].
The Second Approach: Bayesian Model Averaging
In the previous section we discussed the uncertainty with which SNPs belong in a biosignature
of nicotine metabolism. Bayesian approaches can account for this uncertainty in the model
speciﬁcation. Here, the posterior probability for a given model is:
pðMjDÞ ¼ pðDjMÞpðMÞP
m2M pðDjmÞpðmÞ
Obtaining the denominator would involve exploring all possible biosignatures which may not be
computationally feasible. Thus the posterior probability is usually approximated by assessing
the relative merit of a subset of models [56].228 Trends in Molecular Medicine, February 2018, Vol. 24, No. 2
The likelihood above is actually marginalized over the parameters in the model and again is
often approximated.
pðDjMÞ ¼
Z
b
pðDjb; MÞpðbÞdb
The priors on the model p(M) and its parameters p(b) can give us the opportunity to formally
introduce existing results, knowledge bases, and assumptions into the modeling [57]; for
example, what variables are biologically important, the direction and magnitude of their effects,
and the certainty with which they are involved. In fact, most penalized regression approaches
can also be represented by specifying priors on p(b) [48].
More complex relationships among variables can also be learned from the data. Combinations
of SNPs or other factors can be condensed into new derived variables Zj. For example, tree
structures, denoted L, can be considered where the output of each node is determined by its
input values and a set of edge parameters [58]. One such tree structure is shown in Figure 5
and represents the following system of equations:
Z1 ¼ u1;1G1 þ u1;2G2 þ ð1  u1;1  u1;2ÞG1G2
Z2 ¼ u2;1G3 þ u2;2G4 þ ð1  u2;1  u2;2ÞG3G4
Z3 ¼ u3;1Z1 þ u3;2Z2 þ ð1  u3;1  u3;2ÞZ1Z2
These tree-based derived variables provide a very ﬂexible way of representing interactions [58].
For example, given binary inputs, different edge parameters can represent different operators.
If u1 = u2 = 0.5, the effects are additive; if u1 = u2 = 0 there is an effect only when both variants
are present (logical AND); and if u1 = u2 = 1 there is an effect if either variant is present (logical
OR). The effects of the derived variables represent the net effect of the tree [58].
Under this theme, every pairwise SNP effect on nicotine metabolism can be considered (over 6
million derived variables). The evidence for or against each can be computed using Bayes
factors, the ratio of posterior to prior odds. The top associations are shown in Figure 6. Seven
genomic regions showed evidence of interactions. The CYP2A6 region is an important hub,
with other genetic variants near UGT2B10, UGT1A4/A9, POR, NR1I3, NFE2L2, and HNF4A,
contributing to its effects on nicotine metabolism (Figure 6).
More complex combinations (starting with one tree and then modifying it to ﬁnd better
combinations) can be sought. This process can be repeated hundreds of thousands of times.
Combinations of variants that had large impacts on nicotine metabolism were found. For
example, the best learned model had a posterior probability of 0.90%, explained 43% of
nicotine metabolism, and had a rather large effect on natural log NMR (bL =1.35). As in
penalized regression, multiple models ﬁt the data well, but the posterior probabilities provide an
intuitive way to average models [54,55]. Trees with the highest posterior probabilities contained
a handful of SNPs and had strikingly similar measures of ﬁt [53]. This suggests that one should
make nicotine metabolism predictions by averaging over the collection of models. The poste-
rior predictive distribution allowed us to generate predictions of new observations using the
entire distribution of explored biosignatures [59].
Incorporating These Approaches into Research and Clinical Translation
Statistical learning algorithms can help identify biosignatures of SUD outcomes. Once learned,
these models can provide biological insights on their own as well as be applied to existing orTrends in Molecular Medicine, February 2018, Vol. 24, No. 2 229
Figure 5. Tree-Based Structures Can Represent Complex Relationships in Sets of Variables. Here each
derived variable Z is computed from its inputs (genetic variants, clinical factors, or other derived variables) and a pair of
edge parameters u. The regression coefﬁcient b1 represents the net effect of the entire combination of variables on the
outcome of interest Y. These structures were explored using Bayesian algorithms to learn biosignatures of nicotine
metabolism.new data to generate predictions. While the focus of the nicotine metabolism example relied on
genomics, the approach can be applied to other data commonly available or becoming
available in studies of SUDs, such as metabolomic [60,61], personality assessment [62,63],
neuroimaging [64,65], and mobile health applications [66]. The ﬁrst approach described
involves learning using penalized regression algorithms. These algorithms select variables
while simultaneously estimating their effects. As demonstrated in the nicotine metabolism
application, they extract different features from the data. Thus we advocate using the entire
ensemble to characterize the biosignatures. The second approach involves learning a distri-
bution of models and leveraging that distribution in prediction [54]. These Bayesian algorithms
allow us to consider more complex relationships among variables [58]. In the nicotine metabo-
lism example, variants near CYP2A6 and other parts of the pathway jointly inﬂuenced nicotine
metabolism (Figure 6). This suggests that learning algorithms can identify combinations of
genetic variances that explain molecular phenotypes that may be missed using traditional
analyses. The next steps involve validating the biosignatures in other datasets with both
genomic data and nicotine metabolites, and then applying the learned biosignatures and
weights in other datasets, to observe how the biosignatures inﬂuence smoking-related
outcomes.
Many statistical learning approaches have been around for some time, but are just now being
applied to SUDs. Computing used to be a major bottleneck in applying these algorithms. But
with new acceleration computing and software stacks, algorithms are being retooled to handle230 Trends in Molecular Medicine, February 2018, Vol. 24, No. 2
Figure 6. Joint SNP Effects on Nico-
tine Metabolism. The effects of combi-
nation of genetic variant on nicotine
metabolism can be explored using Baye-
sian algorithms [58]. This plot shows that
many genetic variants (dots) in different
genes (color) can modify the effects of
CYP2A6 variants on nicotine metabolism.
This presents another way of deﬁning
biosignatures from a collection of models
for use in prediction or generating new
hypotheses.much larger and more complex datasets. As in all industries, data is now in abundance. There
are more data on individuals with SUDs available now than ever before [67]. Several groups
have begun to explore applying these algorithms to learn predictors of response to treatment
for SUDs [68–70], but this is just the beginning of a new wave of discovery. There has been a
recent increase of deep learning algorithms being applied to health applications: automatic
detection of new tumors from imaging data [71], discovery of new drug targets [72], and
precision treatments in cancer patientsii. The availability of data, computation, and algorithms
have profound implications for the future of biosignature and biomarker development in SUD
screening, diagnosis, and treatment.
Retrospective biomarker/biosignature discovery has strengths (available data) and weak-
nesses (older, possibly less-relevant trials, biospecimen availability) or biases (lack of biospeci-
mens, older molecular datasets). Similarly, hypothesis-driven prospective biomarker discovery
and validation has strengths (ability to deﬁne variables/study domains, state-of-the-art bio-
specimen and biomarker data collection) and weaknesses (candidate hypotheses may miss
predictive biomarker variables/domains). The choice of a retrospective versus a prospective
approach may depend upon currently available resources or the ability to leverage existing
public datasets. A prospective discovery and validation design offers the theoretical ability to
include all domains or selected (hypothesis-driven) domains; the former is limited by practical
considerations and the latter may unfortunately restrict variable discovery. The necessity of
validation for replication, and clinical utility analysis to fulﬁll regulatory and reimbursement
requirements, means that designing discovery and validation studies will involve both retro-
spective and prospective designs. Excluding logical incompatibilities, practical and contingent
limitations are more likely to limit or slow biosignature development and translation to practice
than the choice of study design or whether either type of design is hypothesis driven.
Guidelines for biomarker development and translation to treatment of omics-based tests has
been a hot topic for almost a decade [73,74]. Omics-based tests are deﬁned as an assay
composed of or derived from many molecular measurements and interpreted by a fullyTrends in Molecular Medicine, February 2018, Vol. 24, No. 2 231
Outstanding Questions
What tools can be developed to help
researchers accelerate SUD bio-
marker/biosignature innovation?
Learning algorithms need high-quality
data to grow models. Current chal-
lenges include culture (data sharing),
data merging, and patient consent and
regulatory issues.
How will predictive biosignatures or
learning algorithms be clinically vali-
dated? Traditional biomarker develop-
ment emphasizes a discovery to
clinical validation path, followed by
evaluation of a ﬁxed model for clinical
utility and use. How will this be
adapted for versioned biosignatures
in a continuous improvement system?
What best practices should there be to
encourage innovation, yet maintain
patient safety?
What are the challenges of deploying
these models into healthcare sys-
tems? Predictive biosignatures should
be applicable across demographics
and environments by qualiﬁcation
across diverse populations. Enabling
comparative effectiveness evaluation
will require data sharing across regions
and practice environments.
Box 2. Clinician's Corner
Biomarkers of SUDs are now used clinically to detect substance use and relapse from abstinence. Emerging biomarkers
will enable stratiﬁcation of diagnosed SUD patients for greatest therapy efﬁcacy.
Future SUD biosignatures will aggregate multiple predictors through omic analysis and statistical learning and
dramatically expand diagnostic and predictive utility.
Translation of SUD biosignatures into clinical care requires support for clinical biospecimen testing and clinical
counseling.
Improving the effectiveness of SUD biosignatures will be facilitated by integration of SUD biosignature assessment and
counseling into clinical care – as smoking status assessment has become routine in multiple medical specialties.speciﬁed computational model to produce a clinically actionable result [74]. There are currently
no regulatory guidelines on versioning of biosignatures whose speciﬁcations may adapt and
improve with more data (Figure 1). Current guidelines require that biomarker tests for any
application be ﬁxed before moving into a clinical trial for assessment of their utility [74,75].
Additionally, evidence is evaluated based on study design, the complexity of the bioassay, and
the nature of the mathematical model [76,77]. Many challenges remain in the translation of
biosignatures to clinical care; the guidelines, roadmap, and regulatory ecosystem will need to
be recalibrated as models and predictions become more dynamic.
Some progress has been made in developing dynamic systems that collect and analyze data
from its own processes in order to improve outcomes. Recommendations for development of a
rapid learning system for biomarkers encompassing policy, data infrastructure, and patient
care are part of an evolutionary process of the biomedical enterprise [74]. This represents an
extension of older ideas of a learning [78], continuously improving [79], and genomics-enabled
learning [80] healthcare system. Adding biosignature discovery and translation to these ideas
implies much greater efforts to align patient care and provider and healthcare system practice
than introduction of a single biomarker with a single context of use. The challenges of
biosignature translation have perhaps been most thoroughly addressed in oncology
[81,82]. However, guidance is emerging on the multiple domain challenges [83,84], the general
pathway for biomarker qualiﬁcation [85], and biomarkers for speciﬁc SUDs [86,87].
Concluding Remarks
Here, new strategies for biosignature development have been described that acknowledge the
complexities of disease and data and touch on the ongoing challenges of translation to clinical
care. In both biosignature development and in translation to clinical care, complex challenges
require comprehensive, integrated solutions. We encourage addiction researchers to share
data, organize themselves to enable secondary data analyses, and consider applying these
and other learning algorithms to their data to generate new biological insights and prediction
models. We realize there are some remaining big questions on how the strategy presented ﬁts
into existing biomarker development, clinical translation, and regulation paradigms (see Out-
standing Questions and Box 2). There is a delicate balance between encouraging standardi-
zation and enabling a learning healthcare system that requires scientiﬁc and regulatory
leadership to advance biosignatures into clinical care.
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